CXCL17 and gastric cancer: In GC, although CXCL17 expression gradually increases in precancerous lesions but significantly decreases in gastric cancer tissues, GPR35 remains consistently highly expressed, suggesting that CXCL17 loss and GPR35 activation may jointly promote gastric cancer progression by upregulating CCL20 to reshape the immune microenvironment (52).